Literature DB >> 22173093

Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: solution behavior, reactions with model proteins, antiproliferative properties.

Laura Maiore1, Maria Agostina Cinellu, Stefania Nobili, Ida Landini, Enrico Mini, Chiara Gabbiani, Luigi Messori.   

Abstract

Gold(III) compounds form a family of promising cytotoxic and potentially anticancer agents that are currently undergoing intense preclinical investigations. Four recently synthesized and characterized gold(III) derivatives of 2-substituted pyridines are evaluated here for their biological and pharmacological behavior. These include two cationic adducts with 2-pyridinyl-oxazolines, [Au(pyox(R))Cl(2)][PF(6)], [pyox(R)=(S)-4-benzyl-2-(pyridin-2-yl)-4,5-dihydrooxazole, I; (S)-4-iso-propyl-2-(pyridin-2-yl)-4,5-dihydrooxazole, II] and two neutral complexes [Au(N,N'OH)Cl(2)], III, and [Au(N,N',O)Cl], IV, containing the deprotonated ligand N-(1-hydroxy-3-iso-propyl-2-yl)pyridine-2-carboxamide, N,N'H,OH, resulting from ring opening of bound pyox(R) ligand of complex II by hydroxide ions. The solution behavior of these compounds was analyzed. These behave as classical prodrugs: activation of the metal center typically takes place through release of the labile chloride ligands while the rest of the molecule is not altered; alternatively, activation may occur through gold(III) reduction. All compounds react eagerly with the model protein cyt c leading to extensive protein metalation. ESI MS experiments revealed details of gold-cyt c interactions and allowed us to establish the nature of protein bound metal containing fragments. The different behavior displayed by I and II compared to III and IV is highlighted. Remarkable cytotoxic properties, against the reference human ovarian carcinoma cell lines A2780/S and A2780/R were disclosed for all tested compounds with IC(50) values ranging from 1.43 to 6.18 μM in the sensitive cell line and from 1.59 to 10.86 μM in the resistant one. The common ability of these compounds to overcome cisplatin resistance is highlighted. The obtained results are thoroughly discussed in the frame of current knowledge on cytotoxic gold compounds. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22173093     DOI: 10.1016/j.jinorgbio.2011.11.007

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  4 in total

Review 1.  Interactions of Nanoparticles and Biosystems: Microenvironment of Nanoparticles and Biomolecules in Nanomedicine.

Authors:  Carlota Auría-Soro; Tabata Nesma; Pablo Juanes-Velasco; Alicia Landeira-Viñuela; Helena Fidalgo-Gomez; Vanessa Acebes-Fernandez; Rafael Gongora; María Jesus Almendral Parra; Raúl Manzano-Roman; Manuel Fuentes
Journal:  Nanomaterials (Basel)       Date:  2019-09-24       Impact factor: 5.076

2.  Synthesis, Characterization, and Antiproliferative Activity of Novel Chiral [QuinoxP*AuCl2]+ Complexes.

Authors:  Adedamola S Arojojoye; R Tyler Mertens; Samuel Ofori; Sean R Parkin; Samuel G Awuah
Journal:  Molecules       Date:  2020-12-04       Impact factor: 4.411

3.  Anticancer Activity and Apoptosis Induction of Gold(III) Complexes Containing 2,2'-Bipyridine-3,3'-dicarboxylic Acid and Dithiocarbamates.

Authors:  Ali Alhoshani; Adam A A Sulaiman; Homood M As Sobeai; Wajhul Qamar; Moureq Alotaibi; Khalid Alhazzani; Muhammad Monim-Ul-Mehboob; Saeed Ahmad; Anvarhusein A Isab
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

Review 4.  Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy?

Authors:  Chien Ing Yeo; Kah Kooi Ooi; Edward R T Tiekink
Journal:  Molecules       Date:  2018-06-11       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.